Aegis Still Positive on Catalyst (CPRX) Following Q4 Results; Credit for Firdapse Still Not Given

March 19, 2014 11:20 AM

Aegis Capital reaffrms its Buy rating and $6 price target on Catalyst Pharmaceutical Partners Inc. (Nasdaq: CPRX) following Q4 results ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found